Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18124821 | 0.95 | LIPG (0.50) | LPLLIPGMAPK1CA1CA2 | |
| SCHEMBL20745594 | 0.94 | LPL (0.43) | LPLLIPGTSHRKDM4EMAPK1 | |
| SCHEMBL15075295 | 0.93 | MAPK1 (0.49) | LPLLIPGTSHRKDM4EMAPK1 | |
| SCHEMBL431636 | 0.90 | LIPG (0.46) | LPLLIPGTSHRKDM4EMAPK1 | |
| SCHEMBL2801619 | 0.89 | LPL (0.51) | LPLLIPGTSHRALDH1A1 | |
| SCHEMBL517519 | 0.88 | DGAT1 (0.46) | LPLLIPGTSHRLMNASMN1; SMN2 | |
| SCHEMBL23732854 | 0.87 | LIPG (0.46) | LPLLIPGTSHRCA1CA2 | |
| SCHEMBL4602862 | 0.87 | LPL (0.49) | LPLLIPGTSHRCA1CA2 | |
| SCHEMBL1561441 | 0.87 | LIPG (0.46) | LPLLIPGKDM4EALDH1A1LMNA | |
| SCHEMBL15941126 | 0.87 | LIPG (0.46) | LPLLIPGTSHRALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20140346486-A1 | LIGHT EMITTING COMPOSITION AND DEVICE | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20140346486-A1 | LIGHT EMITTING COMPOSITION AND DEVICE | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | LPL 1608/4885LIPG 1317/4885TSHR 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.